These Two ‘Omics’ Companies are Merging to Create a New Player in Life Sciences

15/07/2016 - 4 minutes

Sygnis is planning to acquire Expedeon, to join its portfolio in NGS reagents with Expedeon’s presence in the proteomics market – and become a leading player in life science reagents.

UPDATE (article originally published on June 6th, 2016): Sygnis successfully completes Rights Offering and Private Placement and secured the acquisition of Expedeon Holdings Ltd. on July 15th, 2016. See the end of the article for more details.

sygnis_dna_genomics_expedeon_proteomicsHeadquartered in Germany and Spain, Sygnis develops products for genomic research, such as kits to amplify DNA and systems to ‘convert’ RNA into DNA – making RNA analysis easier.

Its present focus is facilitating next-generation sequencing (NGS) and the huge role it could play in personalized medicine.

Sygnis also eyed the emerging proteomics field. It developed Double Switch (now licensed to Thermo Fisher), a tool to detect and quantify protein interaction – an added layer of complexity in biology that cannot be ‘seen’

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member